TrialLineage Concept
CNS drug delivery
The central nervous system (CNS) — brain and spinal cord — is protected by the blood-brain barrier, which prevents most circulating molecules from reaching neural tissue. Delivering drugs to the CNS requires specialized strategies: intrathecal injection, blood-brain barrier penetration, or direct CNS administration.
In plain language
Why the brain is hard to treat
The blood-brain barrier (BBB) is a layer of tightly connected cells lining the brain’s blood vessels. It protects the brain from toxins and pathogens but also blocks most therapeutic molecules. Large molecules like antibodies, oligonucleotides, and gene therapy vectors generally cannot cross the BBB when administered intravenously.
Intrathecal delivery — injection into the cerebrospinal fluid surrounding the spinal cord — bypasses the BBB entirely. The drug distributes through the fluid that bathes the brain and spinal cord, reaching neural tissue directly. This route is invasive (requiring a lumbar puncture) but effective for molecules like ASOs.
Why CNS delivery matters for RNA therapies
ASOs do not readily cross the blood-brain barrier. For neurological diseases like Angelman syndrome and spinal muscular atrophy, intrathecal delivery is the established route. Nusinersen (Spinraza), the first approved ASO for a CNS disease, validated that intrathecal administration could achieve therapeutic ASO concentrations in the spinal cord and brain.
ION582 uses the same intrathecal delivery approach. The drug is injected into the cerebrospinal fluid, where it distributes to neurons throughout the CNS. Repeat dosing is required because ASOs are gradually cleared, and the silencing of paternal UBE3A presumably re-establishes as ASO levels decline.
Position in the scientific lineage
CNS delivery is one of the enabling steps that made intrathecal ASO therapy feasible. Without a validated route to get oligonucleotides into neural tissue, the biological rationale for targeting UBE3A-ATS would have remained laboratory science. The clinical success of nusinersen de-risked the delivery question and made ION582 development possible.
Related concepts